{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HPV16+Positive&page=2", "query": { "condition": "HPV16 Positive", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HPV16+Positive&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T03:39:04.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04646005", "title": "Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "ISA101b", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 113, "start_date": "2021-06-28", "completion_date": "2024-05-29", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 3, "location_summary": "Tucson, Arizona • Orange, California", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04646005" }, { "nct_id": "NCT02865135", "title": "Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer of Head and Neck", "Cancer of Cervix", "Cancer of Anus" ], "interventions": [ { "name": "DPX-E7 vaccine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-03-30", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02865135" }, { "nct_id": "NCT05973487", "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Cervical Cancer", "Non-small Cell Carcinoma", "Melanoma", "Ovarian Cancer", "Anogenital Cancers", "HPV - Anogenital Human Papilloma Virus Infection", "HPV-Related Cervical Carcinoma", "HPV-Related Carcinoma", "HPV-Related Squamous Cell Carcinoma", "HPV-Related Malignancy", "HPV-Related Adenocarcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Related Adenosquamous Carcinoma", "HPV-Associated Vaginal Adenocarcinoma", "HPV-Related Endocervical Adenocarcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Verrucous Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma", "HPV Positive Rectal Squamous Cell Carcinoma" ], "interventions": [ { "name": "TSC-204-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-C0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-200-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-204-A0101", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-201-B0702", "type": "BIOLOGICAL" }, { "name": "TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-C0702 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-200-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-203-A0201 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-204-A0101 + TSC-202-A0201", "type": "BIOLOGICAL" }, { "name": "TSC-201-B0702 + TSC-202-A0201", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TScan Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-05-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973487" }, { "nct_id": "NCT07290621", "title": "Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Cancer" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-02", "completion_date": "2033-02", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290621" }, { "nct_id": "NCT02280811", "title": "T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Vaginal Cancer", "Cervical Cancer", "Anal Cancer", "Penile Cancer", "Oropharyngeal Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "E6 TCR", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 12, "start_date": "2014-10-14", "completion_date": "2016-06-28", "has_results": true, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02280811" }, { "nct_id": "NCT04001413", "title": "Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Oropharynx Cancer", "HPV-Related Carcinoma" ], "interventions": [ { "name": "MEDI0457", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-09-17", "completion_date": "2021-03-25", "has_results": false, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 4, "location_summary": "Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001413" }, { "nct_id": "NCT03258008", "title": "Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites", "Malignant Neoplasms of Lip Oral Cavity and Pharynx", "Oropharyngeal Cancer" ], "interventions": [ { "name": "Utomilumab", "type": "DRUG" }, { "name": "ISA101b", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-04-04", "completion_date": "2021-11-05", "has_results": true, "last_update_posted_date": "2022-12-16", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258008" }, { "nct_id": "NCT04180215", "title": "A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HPV-Related Squamous Cell Carcinoma" ], "interventions": [ { "name": "HB-201 intravenous administration.", "type": "DRUG" }, { "name": "HB-202 intravenous administration alternating with HB-201 intravenous administration.", "type": "DRUG" }, { "name": "HB-201 intravenous administration + standard of care regimen including pembrolizumab.", "type": "DRUG" }, { "name": "HB-202 / HB-201 alternating intravenous administration + pembrolizumab.", "type": "DRUG" }, { "name": "HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.", "type": "DRUG" }, { "name": "HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hookipa Biotech GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2019-12-11", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180215" }, { "nct_id": "NCT04630353", "title": "A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer" ], "interventions": [ { "name": "HB-201 IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hookipa Biotech GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-07-28", "completion_date": "2023-11-28", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630353" }, { "nct_id": "NCT04260126", "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Cancer", "Recurrent Head and Neck Cancer", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Pembrolizumab (KEYTRUDA®) and PDS0101", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "PDS Biotechnology Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2021-03-29", "completion_date": "2025-05-14", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-05-22T03:39:04.473Z", "location_count": 18, "location_summary": "Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04260126" } ] }